论文部分内容阅读
目的观察美托洛尔联合稳心颗粒治疗冠心病、室性期前收缩、NT-proBNP的临床疗效和安全性。方法对符合纳入标准的病例采取随机双盲对照。随机分为两组,治疗组给予:美托洛尔2次/d,25mg/次,稳心颗粒3次/d、1包/次,疗程8周;对照组:美托洛尔2次/d、25mg/次,疗程8周。8周后对冠心病临床症状、心电图改变,室性期前收缩,NT-proBNP的疗效及毒副作用进行评估。结果 8周后治疗组心电图改善显效率为60%,总有效率为86.67%,明显优于对照组的显效率50%和总有效率80%(P<0.01)。8周后临床症状改变,治疗组显效60%,总有效率93.33%,明显优于对照组43.33%和总有效率86.67%。8周后NT-proBNP明显下降治疗组优于对照组(P<0.05)。结论美托洛尔联合稳心颗粒治疗冠心病、室性期前收缩、NT-proBNP的疗效确切,且无明显毒副作用。
Objective To observe the clinical efficacy and safety of metoprolol combined with Wenxin Granule in treating coronary heart disease, ventricular premature ventricular contraction and NT-proBNP. Methods Randomized double-blind controls were performed on eligible patients. Patients were randomly divided into two groups: metoprolol 2 times / d, 25mg / times, Wenxin granules 3 times / d, 1 package / time for 8 weeks; control group: metoprolol 2 times / d, 25mg / time, treatment for 8 weeks. Eight weeks later, clinical symptoms, ECG changes, ventricular premature ventricular contraction, the efficacy of NT-proBNP and toxicity were evaluated. Results After 8 weeks, the effective rate of electrocardiogram improvement was 60% and the total effective rate was 86.67% in the treatment group, which was significantly better than that of the control group (50%) and total effective rate (80%) (P <0.01). After 8 weeks, the clinical symptoms were changed. The treatment group was 60% effective and the total effective rate was 93.33%, which was obviously superior to the control group and 43.33% and the total effective rate was 86.67%. After 8 weeks NT-proBNP decreased significantly in treatment group than in control group (P <0.05). Conclusions Metoprolol combined with Wenxinkeli in the treatment of coronary heart disease, premature ventricular contraction, NT-proBNP has the exact effect, and no obvious side effects.